{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:55:40Z","timestamp":1793404540853,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jacc.2023.07.031","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T13:57:18Z","timestamp":1696859838000},"page":"1565-1578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks"],"prefix":"10.1016","volume":"82","author":[{"given":"Seokhun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ho","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doyeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1548-2351","authenticated-orcid":false,"given":"Han-Mo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Suk","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2063-1542","authenticated-orcid":false,"given":"Sang-Ho","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Kean","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il-Woo","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Ill","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-0747","authenticated-orcid":false,"given":"Jung-Kyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-6968","authenticated-orcid":false,"given":"Eun-Seok","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bon-Kwon","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-5329","authenticated-orcid":false,"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.07.031_bib1","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.07.031_bib2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.07.031_bib3","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.07.031_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.07.031_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009642","article-title":"Relative impact of clinical risk versus procedural risk on clinical outcomes after percutaneous coronary intervention","volume":"14","author":"Kang","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2023.07.031_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.21326","article-title":"Trends in\u00a0characteristics and outcomes of patients undergoing coronary revascularization in the United States, 2003-2016","volume":"3","author":"Alkhouli","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2023.07.031_bib7","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2020.07.037","article-title":"Comparative trends in percutaneous coronary intervention in Japan and the United States, 2013 to 2017","volume":"76","author":"Inohara","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.07.031_bib8","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2021.08.074","article-title":"Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI","volume":"78","author":"Valgimigli","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.07.031_bib9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.115.019861","article-title":"Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.07.031_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2337\/dc17-1736","article-title":"Risk assessment in patients with diabetes with the TIMI risk score for atherothrombotic disease","volume":"41","author":"Bergmark","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2023.07.031_bib11","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.07.031_bib12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.07.031_bib13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jcin.2020.01.211","article-title":"The DAPT score uncouples bleeding and ischemic risk...again","volume":"13","author":"Yeh","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2023.07.031_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2016.12.001","volume":"185","author":"Lee","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2023.07.031_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.07.031_bib16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(13)61752-3","article-title":"The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective","volume":"383","author":"Mahmood","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.07.031_bib17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/eurheartj\/ehi187","article-title":"TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS","volume":"26","author":"de Araujo Goncalves","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.07.031_bib18","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1007\/s00380-021-01840-z","article-title":"Validation of the atherothrombotic risk score for secondary prevention in patients with acute myocardial infarction: the J-MINUET study","volume":"36","author":"Hashimoto","year":"2021","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacc.2023.07.031_bib19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jacc.2018.06.023","article-title":"External validation of the DAPT score in a nationwide population","volume":"72","author":"Ueda","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.07.031_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006853","article-title":"Prediction of ischemic and bleeding events using the dual antiplatelet therapy score in an unrestricted percutaneous coronary intervention population","volume":"11","author":"Brener","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2023.07.031_bib21","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1160\/TH17-02-0101","article-title":"Validation of the DAPT score in patients randomized to 6 or 12\u00a0months clopidogrel after predominantly second-generation drug-eluting stents","volume":"117","author":"Harada","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2023.07.031_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/M16-2389","article-title":"Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention","volume":"167","author":"Piccolo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2023.07.031_bib23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/CIRCULATIONAHA.117.028924","article-title":"Validating utility of dual antiplatelet therapy score in a large pooled cohort from 3 Japanese percutaneous coronary intervention studies","volume":"137","author":"Yoshikawa","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.07.031_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2023.07.031_bib25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.07.031_bib26","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.07.031_bib27","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.jcin.2022.08.009","article-title":"P2Y(12) Inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention: a network meta-analysis","volume":"15","author":"Ando","year":"2022","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2023.07.031_bib28","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/01.CIR.0000029926.71825.E2","article-title":"Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups","volume":"106","author":"Budaj","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.07.031_bib29","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or\u00a030\u00a0months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.07.031_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.103.3.363","article-title":"Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery","volume":"103","author":"Bhatt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.07.031_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with\u00a0diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.07.031_bib32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/01.STR.0000110221.54366.49","article-title":"Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events","volume":"35","author":"Ringleb","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2023.07.031_bib33","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/archinte.164.19.2106","article-title":"Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies","volume":"164","author":"Hirsh","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2023.07.031_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1607181","article-title":"Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis","volume":"2019","author":"Paciaroni","year":"2019","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jacc.2023.07.031_bib35","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.mayocp.2022.01.033","article-title":"Effectiveness and safety of clopidogrel vs aspirin in elderly patients with ischemic stroke","volume":"97","author":"Huang","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2023.07.031_bib36","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/STROKEAHA.118.024497","article-title":"Antiplatelet therapy after noncardioembolic stroke","volume":"50","author":"Greving","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2023.07.031_bib37","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacc.2023.07.031_bib38","first-page":"2720","article-title":"Effects of monotherapy with clopidogrel vs. aspirin on vascular function and hemostatic measurements in patients with coronary artery disease: the prospective, crossover I-LOVE-MONO Trial","volume":"10","author":"Park","year":"2021","journal-title":"J\u00a0Clin Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972306463X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972306463X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:58:19Z","timestamp":1760018299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972306463X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":38,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S073510972306463X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.07.031","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}